PhD Scientific Days 2020

Pharmaceutical Sciences I. Posters

Novel Magnetic Prussian Blue Nanoparticles for In Vivo T1 MR-imaging

Előadó neve

Dr. Forgách, László

Előadó munkahelye

Semmelweis University, Department of Biophysics and Radiation Biology

Előadó telefonszáma

+36308921791

Előadó e-mail címe

forgach.laszlo@med.semmelweis-univ.hu

Az előadás címe

Novel Magnetic Prussian Blue Nanoparticles for In Vivo T1 MR-imaging

Szerző(k) neve és munkahelye

László Forgách / Department of Biophysics and Radiation Biology, Semmelweis University, Budapest
Nikolett Hegedűs; Ildikó Horváth; Krisztián Szigeti / Department of Biophysics and Radiation Biology, Semmelweis University, Budapest
Domokos Máthé / Department of Biophysics and Radiation Biology, Semmelweis University, Budapest; CROmed Translational Research Centers, Budapest

Szekció

Pharmaceutical Sciences I. Posters

Language of the presentation

Hungarian

Section, first choice

Pharmaceutical Sciences

Section, second choice

Pharmaceutical Sciences

Összefoglaló szövege

Iron-oxide nanoparticles have long been researched for their superparamagnetic properties. These T2 MRI contrast agents (CAs), which are also called negative CAs, cause a hypointense change of the MR image. This property makes it difficult for the human eyes to detect and diagnose most small tumor details. Currently, Gd and Mn-containing substances are commercially available for this purpose, however, they are known to have toxic effects.
The aim of my work was to develop a Prussian Blue nanoparticle (PBNP) based MRI contrast agent and to investigate its properties in vitro and in vivo, in a mouse model.
For the synthesis, PBNP-AC (citrate coated; biocompatible) and PBNP-HCl (non-biocompatible) PBNPs were used in different ratios. The degree of dispersion (PDI) and stability of the system was checked by Dynamic light scattering (DLS). During in vitro MRI measurements T1 and T2 relaxivity of my samples was compared with the CAs widely used in the clinical practice. An authorized radiopharmaceutical, Gadovist (T1 CA) and with Salsol (T2 CA) were the contoll probes. Subsequently, in my in vivo experiment I used only the sample with best relaxation time, compared to the T1 controll. The stability of the prepared system was examined for 6 weeks. In vitro MRI scans clearly show the change in signal intensity caused by different compositions of samples. Evaluating the resulting T1 and T2 weighted signal intensity curves, the signal intensity of the PBNP-AC: PBNP-HCl 1: 2 sample was the most appropriate for further in vivo measurement.
After intravenous administration of the CA, the biodistribution of NPs was investigated, which resulted in hyperintense changes on T1-weighted images, while on T2-weighted images hypointense changes were observed e.g. in the vascular system compared to the surrounding tissues.
As a conclusion, I successfully developed and tested a Prussian Blue based nanosystem that proved to be a CA for in vivo MRI imaging, also as a T1 CA. Considering the previously developed fluorescence labeling and pegylation protocol of the nanosystem, the present compound has a huge potential for innovation in imaging diagnostics.

Additional Information

References:
1. STEPHEN, Zachary R.; KIEVIT, Forrest M.; ZHANG, Miqin. Magnetite nanoparticles for medical MR imaging. Materials Today, 2011, 14.7-8: 330-338.
2. SZIGETI, Krisztián, et al. Thallium labeled citrate-coated prussian blue nanoparticles as potential imaging agent. Contrast media & molecular imaging, 2018, 2018.

Bemutatás módja

Poszter

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

4766

Start

11:22

End

11:25

Authors (legacy)

László Forgách / Department of Biophysics and Radiation Biology, Semmelweis University, Budapest
Nikolett Hegedűs; Ildikó Horváth; Krisztián Szigeti / Department of Biophysics and Radiation Biology, Semmelweis University, Budapest
Domokos Máthé / Department of Biophysics and Radiation Biology, Semmelweis University, Budapest; CROmed Translational Research Centers, Budapest